theory clinical_3_0
imports Main

begin

typedecl entity
typedecl event

consts
  LossOfBRCA2 :: "entity ⇒ bool"
  ChromosomeBreakage :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  InhibitionOfPARP :: "entity ⇒ bool"
  CollapsedReplicationForks :: "entity ⇒ bool"
  DoubleStrandBreak :: "entity ⇒ bool"
  Result :: "event ⇒ bool"
  CancerDevelopment :: "entity ⇒ bool"
  GenomicInstability :: "entity ⇒ bool"
  Drive :: "event ⇒ bool"
  Via :: "event ⇒ entity ⇒ bool"
  TrappingOfPARP1 :: "entity ⇒ bool"
  SitesOfDoubleStrandBreaks :: "entity ⇒ bool"
  NonHomologousEndJoining :: "entity ⇒ bool"
  Toxicity :: "entity ⇒ bool"
  Increase :: "event ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  DoubleStrandBreaks :: "entity ⇒ bool"
  SingleStrandBreakRepair :: "entity ⇒ bool"
  Prevent :: "event ⇒ bool"
  RelyOn :: "event ⇒ bool"
  DefectiveHomologousRecombinationRepair :: "event ⇒ bool"
  ErrorProneNonHomologousEndJoining :: "event ⇒ bool"
  RepairDNA :: "event ⇒ bool"

(* Explanation 1: loss of BRCA2 causes chromosome breakage *)
axiomatization where
  explanation_1: "∀x y e. LossOfBRCA2 x ∧ ChromosomeBreakage y ⟶ (Cause e ∧ Agent e x ∧ Patient e y)"

(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand break *)
axiomatization where
  explanation_2: "∀x y z e. InhibitionOfPARP x ∧ CollapsedReplicationForks y ∧ DoubleStrandBreak z ⟶ (Result e ∧ Agent e x ∧ Patient e y ∧ Patient e z)"

(* Explanation 3: loss of BRCA2 drives cancer development via genomic instability *)
axiomatization where
  explanation_3: "∀x y z e. LossOfBRCA2 x ∧ CancerDevelopment y ∧ GenomicInstability z ⟶ (Drive e ∧ Agent e x ∧ Patient e y ∧ Via e z)"

(* Explanation 4: Proposal: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity *)
axiomatization where
  explanation_4: "∀x y z e1 e2. TrappingOfPARP1 x ∧ SitesOfDoubleStrandBreaks y ∧ NonHomologousEndJoining z ∧ Toxicity z ⟶ (Increase e1 ∧ Agent e1 x ∧ Patient e1 z ∧ Increase e2 ∧ Agent e2 x ∧ Patient e2 z)"

theorem hypothesis:
  assumes asm: "PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z"
  (* Hypothesis: PARP inhibitors cause replication‐associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA *)
  shows "∃x y z e1 e2 e3 e4. PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z ⟶ (Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ RelyOn e3 ∧ Agent e3 x ∧ DefectiveHomologousRecombinationRepair e3 ∧ RelyOn e4 ∧ Agent e4 x ∧ ErrorProneNonHomologousEndJoining e4 ∧ RepairDNA e4)"
proof -
  (* From the premise, we have known information about PARP inhibitors, double strand breaks, and single strand break repair. *)
  from asm have "PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z" by auto
  (* Explanation 2 suggests that inhibition of PARP results in double strand breaks. *)
  (* We can infer that PARP inhibitors cause double strand breaks. *)
  then have "Cause e1 ∧ Agent e1 x ∧ Patient e1 y" sledgehammer
  (* Explanation 4 suggests trapping of PARP1 increases non-homologous end joining. *)
  (* We can infer that PARP inhibitors rely on error-prone non-homologous end joining. *)
  then have "RelyOn e4 ∧ Agent e4 x ∧ ErrorProneNonHomologousEndJoining e4" <ATP>
  (* We also need to show that PARP inhibitors prevent single strand break repair. *)
  then have "Prevent e2 ∧ Agent e2 x ∧ Patient e2 z" <ATP>
  (* Finally, we need to show reliance on defective homologous recombination repair. *)
  then have "RelyOn e3 ∧ Agent e3 x ∧ DefectiveHomologousRecombinationRepair e3" <ATP>
  (* Combine all parts to conclude the hypothesis. *)
  then show ?thesis <ATP>
qed

end
